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Objective: To compare the efﬁcacy of patient education and supervised exercise with that of patient
education alone for the management of pain in patients with hip osteoarthritis (OA).
Design: Single blind randomized clinical trial.
Setting: Recruitment of patients from hospitals, primary health care and advertisement, Oslo, Norway.
Participants: 109 patients with radiographic and symptomatic hip OA with mild to moderate symptoms.
Interventions: Patient education (PE). Patient education and supervised exercise (PEþ SE).
Primary outcome measure: The pain subscale of the Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC pain).
Results: No signiﬁcant between group differences were found for WOMAC pain over the 16-month
follow-up. Signiﬁcant improvements were found for the secondary outcome WOMAC physical function
(P¼ 0.011) in the group receiving PEþ SE compared to the group receiving PE only. No signiﬁcant
differences were found for WOMAC stiffness, the SF-36 subscales or the activity scale. The effect sizes
(95% conﬁdence interval) for WOMAC pain were 0.26 (0.11, 0.64), 0.35 (0.07, 0.77), and 0.30
(0.15, 0.75), and for WOMAC physical function 0.29 (0.09, 0.67), 0.48 (0.06, 0.91), and 0.47
(0.02, 0.93) at 4, 10 and 16 months, respectively, in favor of the group receiving both PE and SE. All
patients attended the three-session PE program, and 75% performed 16 sessions of the 12-week SE
program.
Conclusion: The study could not demonstrate a signiﬁcant difference in pain reduction over time between
PEþ SE vs PE alone. Adding SE to PE may improve physical function, but the magnitude of possible
beneﬁt is unknown as the 95% conﬁdence intervals around the mean difference were wide.
Trial registration: Clinical Trials NCT00319423.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is reported to be one of the most disabling
diseases in high-income countries1,2. OA predominantly affects hip
and knee joints with pain, stiffness, and limitation in physical
function. For the purpose of reducing pain and improving physical
function in patients with hip and knee OA, 28 out of 34 clinical
guidelines recommended patient education (PE) and 27 out of 34o: L. Fernandes, Norwegian
artment of Orthopedics, Oslo
. Fernandes).
s Research Society International. Precommended strengthening exercises3. Since the evidence upon
which these guidelines primarily comes from randomized
controlled trials (RCTs) including patients with either knee or
multiple-site OA, the evidence level for the recommendations in
patients with isolated hip OA has been considered to be low4e6. In
a recent meta-analysis, in which the authors accessed hip joint
speciﬁc data from RCTs evaluating the effect of exercise in patients
with both hip and knee OA, it was concluded that exercise had
a moderate effect on pain in patients with hip OA7. The authors also
emphasized that as only one RCT exists that restricted recruitment
to patients with hip OA, more RCTs evaluating the effect of exercise
for this cohort are needed. Hence, the purpose of the present study
was to compare the beneﬁts of adding a supervised exercise (SE)
program to a PE program, on pain, physical function, health-relatedublished by Elsevier Ltd. All rights reserved.
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over a 16-month period.
Methods
Participants
Patients aged between 40 and 80 yearswho had experienced hip
pain for the past 3 months or longer were screened for inclusion.
Inclusion criteria were a radiographically veriﬁed minimum joint
space <4 mm for patients <70 years old and <3 mm for patients
70 years old8, and a Harris Hip Score (HHS)9 between 60 and 95
points. Thus, the included patients had both radiographic and
symptomatic hip OA. At our institution, a HHS below 60 points has
been used as criteria for total hip replacement (THR) surgery. In
caseswith bilateral OA themost painful hipwas chosen as the index
joint. Patientswere excluded if theyhad a THR in the index joint, had
been diagnosed with knee OA, had knee pain, low back pain, rheu-
matoid arthritis, osteoporosis, cancer, cardiovascular disease and
not tolerate exercise, dysfunction in lower extremities due to acci-
dent or disease, were pregnant, or did not understand Norwegian.
The studywas carried out according to the Helsinki Declaration and
was approved by the regional medical research ethics committee.
Written informed consents were obtained from all patients.Fig. 1. Study ﬂow diagram of participants enrolled in the study. THR¼ total hip replacThe patients were recruited by one university hospital, one local
hospital, one rehabilitation center, general medical practitioners,
and by advertisement in a local newspaper in Oslo, Norway. The
inclusion was performed at the Department of Orthopedics at the
Oslo University Hospital, by one orthopedic surgeon (LN) exam-
ining all radiographs8, and one physical therapist (LF) rating the
patients’ symptoms (HHS)9.
Interventions
The patients were randomized to either a group receiving PE
only or to a group that received patient education and supervised
exercise (PEþ SE) (Fig. 1). Education was therefore offered to all
patients. The PE given was in the form of a previously described
“Hip School” developed for patients with hip OA10. This
comprised three group-based sessions and one individual phys-
ical therapy visit, 2 months after completing the group sessions.
The SE given was a therapeutic exercise program specially
designed for patients with hip OA11. The patients randomized to
the PEþ SE group started exercising within a week after
completing the PE group sessions. The exercise program con-
sisted of 26 different exercises, including warm-up, strength-
ening exercises, functional exercises and ﬂexibility exercises11.
The patients in the PEþ SE group were offered individualement; HHS¼Harris Hip Score; PE¼ patient education; SE¼ supervised exercise.
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to the gym any other weekday for a period of 12 weeks. They
were instructed to perform the exercise program two to three
times a week and were supervised during the exercise program
at least once weekly. The supervision was performed by a phys-
ical therapist in order to individualize the exercise program to
each patient’s ability. This included selecting exercises from the
26 predetermined exercises, and setting the training dose and
progression accurately11. Both the education and the exercise
program were conducted at our rehabilitation center (Hjelp24-
NIMI) in Oslo, Norway, and led by physical therapists specialized
in orthopedic and/or sports physiotherapy.
Outcome measures
The primary outcome measure was the pain subscale of the
Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) with visual analogue scales (WOMAC pain). TheWOMAC
is a self-administered and disease-speciﬁc outcome specially
designed for patients with hip or knee OA. A normalized subscale
score was calculated for each dimension and expressed best to
worst on a 0e100 scale12. Psychometric studies have shown
moderate to high validity and reliability for the WOMAC13e15.
Secondary outcomes were the stiffness and physical function
subscales of the WOMAC with visual analogue scales (WOMAC
stiffness and WOMAC physical function), the health-related quality
of life questionnaire SF-36v2 and themodiﬁedNorwegianversionof
Physical Activity Score for Elderly (PASE)16,17. The SF-36 consists of
eightmulti-item scales; physical function, role physical, bodily pain,
general health, vitality, social functioning, role emotional, and
mental health. All itemswerenormalized to a scale fromworst (0) to
best (100). The SF-36 has been found to be valid and has high reli-
ability in patients with OA and rheumatoid arthritis15,18. The PASE
registers physical activities performed over the week preceding
testing and the score is calculated fromweight and frequency values
for the activities. Themodiﬁcations done for the Norwegian version
of PASE consisted of both adapting the questionnaire to Norwegian
conditions and excluding question numbers 1 and 2 from the orig-
inal PASE, as the questions were considered redundant17. The
modiﬁed Norwegian PASE ranges from 0 to 315, where “0” repre-
sents no activity at all during the past week and “315” represents an
extremely active week. The PASE is considered reliable and valid for
the registration of activities among older people19e21. The patients
ﬁlled in the self-administered questionnaires at baseline, and at the
4-, 10- and 16-month follow-ups.
Sample size calculation
Based on previous studies on patients with OA we postulated
a mean difference of at least 15 mm of the WOMAC pain score
between the treatment groups at follow-up and a standard devia-
tion of 2322,23. When comparing mean pain scores between the
groups, a two-tailed Student t test with a 5% signiﬁcance level was
used24. In order to have 90% test-power at least 49 patients per
group needed to be included in our trial, however we decided to
include at least 54 patients per group to allowa drop-out rate of 10%.
Randomization and blinding
A blocked randomization list with 10 patients in each block was
computer generated by a statistician (LS) before the inclusion
started. Blocking was used to ensure approximately equal group
sizes. We maintained allocation concealment until written consent
was obtained, baseline assessments were completed, and the
patient had completed the PE group sessions. A researchcoordinator who was not involved in testing or interventions,
opened sealed envelopes containing the randomization allocation
and assigned subjects to the PE group or PEþ SE group accordingly.
The number on the envelope, containing group allocation, corre-
sponded to the consecutive number of the patient. The researchers
were blinded to group allocation throughout the whole trial and
analysis period. No patient in the PE group had access to the SE
program during the intervention period, and could subsequently
not cross over to the PEþ SE group during that period of time. Once
the 4-month follow-up was completed, the patients were free to
visit any physical therapy department or training center they
wanted.
Statistical analyses
Intention-to-treat analyses were performed when comparing
the PE group and the PEþ SE group on efﬁcacy variables for all
participants enrolled in the study, regardless of adherence to the PE
or the PEþ SE25. A linear mixed model (variance component
model) was used when comparing the groups on efﬁcacy variables
with time and the interaction of time and group as ﬁxed effects and
time as random effect intercept and slope (SPSS 16.0, Chicago, IL).
Model assumptions were checked by residual plots (normally
distributed errors) and were found to be adequately fulﬁlled. Mean
difference estimates (95% conﬁdence interval) between groups at
4-, 10-, and 16-month follow-ups for the WOMAC sub-scores were
extracted from the linear mixed model analysis and presented in
a table. Median (inter-quartile range) was used for the description
of adherence to the exercise program, and sub-group per-protocol
analysis on themain outcomewas performed using20 sessions as
cut-off for satisﬁed adherence. Comparisons at baseline were per-
formed with independent samples t test and chi-square test. A
signiﬁcance level of 5%was used. Standardized effect size, known as
Cohen’s d, was estimated for effect size measures for the pain and
physical function subscales of the WOMAC26,27. The effect sizes
were calculated based on the collected data and for sensitivity
analysis also based on the last observation carried forward prin-
ciple. A negative effect size represented a value in favor of the
PEþ SE group, as compared to the PE group.
Results
Two-hundred and two patients were screened for inclusion
during the period April 2005 to October 2007. Of these, 109 fulﬁlled
the inclusion criteria and were randomized (Fig. 1). Recruitment
channels of the included patients are presented in Table I. All
included patients attended the three-session PE. The patients
allocated to the PEþ SE performed a median of 20 (inter-quartile
range 16e24) sessions over the 12-week intervention period, with
a mean of 1.6 exercise sessions per week. Three patients performed
<8 exercises during 15% of their sessions. During all other sessions
the patients in the PEþ SE group performed 8 different exercises.
One patient in the PEþ SE group discontinued exercise after three
sessions because of aggravation of hip pain. No other adverse
events were registered. At the 4-, 10-, and 16-month follow-up,
drop-out rates were 0%, 22%, and 33% for the PE group and 0%, 15%,
and 24% for the PEþ SE group, respectively (Fig. 1). At 16months,11
patients (20%) in the PE group and six patients (11%) in the PEþ SE
group had undergone THR surgery, explaining 55% of the drop-
outs. The patients who were lost to follow-up at 16 months had, at
the last observation before drop-out, a mean(SD) WOMAC pain
score of 39.4(23.5) and 35.2(20.1) mm in the PE and PEþ SE group,
respectively.
At baseline, all variables were similarly distributed with no
signiﬁcant differences between the treatment groups (Tables I and
Table I
Baseline characteristics
Mean SD PE (n¼ 54) PEþ SE (n¼ 55)
Age (years) 57.2 9.8 58.4 10.0
Men/women 26/28 24/31
BMI (kg/m2) 24.9 3.8 24.6 3.2
MJS in target joint (mm) 1.9 1.1 2.1 1.0
HHS (0e100) 76.9 8.2 79.6 7.7
Pain duration (months) 49.5 50.9 47.3 53.3
Uni-/bilateral JSN 16/38 17/38
Number (%)
THR in contralateral hip 2 (3.7) 4 (7.3)
>12 years education 35 (67.3) 43 (78.2)
Employed 36 (66.7) 35 (63.6)
Retired 9 (16.7) 11 (20.0)
Sick-leave 5 (9.3) 8 (14.5)
NSAIDs 9 (16.7) 13 (23.6)
Paracetamol 5 (9.3) 4 (7.2)
Glucosamine 19 (35.2) 13 (23.6)
Other medication 14 (25.9) 10 (18.2)
Recruitment
Hospitals 12 (22.2) 4 (7.3)
Primary care 24 (44.4) 31 (56.4)
Advertisement 7 (13.0) 7 (12.7)
Patients’ friends 3 (5.6) 5 (9.1)
No data on recruitment 8 (14.8) 8 (14.5)
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L. Fernandes et al. / Osteoarthritis and Cartilage 18 (2010) 1237e12431240III). At this time, the patients had signiﬁcantly lower SF-36 physical
function and bodily pain scores than an age matched general
Norwegian population28 (Table II). No signiﬁcant differences in
PASE scores were seen between the included patients and a repre-
sentative elderly Norwegian population at baseline17 (Table II).
Over the 16-month period, no signiﬁcant difference between
the PE group and the PEþ SE groupwas found for theWOMAC pain
score (P¼ 0.15) (Table III). The per-protocol analysis of WOMAC
pain score could not detect any signiﬁcant differences between the
two groups over the 16-month period (P¼ 0.30). The standardized
effect sizes (95% conﬁdence interval) for WOMAC pain scores were
0.26 (0.64 to 0.11), 0.35 (0.77 to 0.07), and 0.30 (0.75 to
0.15) at the 4-, 10- and 16-month follow-ups, respectively. The
standardized effect sizes (95% conﬁdence interval) using the last
observation carried forward principle were 0.33 (0.71 to 0.05)
and 0.31 (0.69 to 0.07) for 10 and 16 months, respectively.Table II
Baseline scores for SF-36 and PASE of included patients and Norwegian
population17,28
Mean SD Patients with hip OA General Norwegian
population28
Men
(n¼ 50)
Women
(n¼ 59)
Men
(n¼ 175)
Women
(n¼ 174)
SF-36 (0e100)
Physical function 71.9 16.1 70.7 19.1 87.2 17.4** 85.6 16.6**
Role physical 80.7 23.6 74.6 25.7 78.0 35.9 77.6 36.2
Bodily pain 63.3 18.8 57.4 16.4 73.2 25.5* 73.8 27.1**
General health 71.3 16.9 67.2 21.8 74.1 22.5 74.7 22.4*
Vitality 62.4 20.3 54.6 19.7 62.4 21.6 62.0 21.0*
Social functioning 91.2 18.4 84.8 22.7 86.5 24.1 86.0 21.3
Role emotional 94.6 14.0 91.5 18.2 87.5 27.9 84.3 30.9
Mental health 83.2 13.8 81.0 14.5 79.7 16.0 79.5 17.3
Patients with hip OA Elderly Norwegian
population17
Men and women (n¼ 107) Men and women (n¼ 343)
PASE (0e315) 118.5 47.2 126.9 73.0
Analysis took into account independent samples t test. *Signiﬁcant level <0.05.
**Signiﬁcant level <0.001. Ta
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Table IV
Mean difference (95% conﬁdence interval) between PE and PEþ SE groups at 4, 10
and 16 months
WOMAC 4 months 10 months 16 months
Pain 4.7 (11.3, 1.9) 6.5 (13.9, 0.7) 4.9 (12.8, 2.9)
Stiffness 3.5 (12.0, 4.9) 6.3 (15.8, 3.1) 11.1 (21.1, 1.0)*
Physical function 4.6 (10.6, 1.5) 8.4 (15.1, 1.7)* 7.7 (14.9, 0.5)*
Linear mixed model (variance component model) with time and time group as
ﬁxed effects, and time as random effect intercept and slope. *Signiﬁcance level
P< 0.05.
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group in WOMAC physical function score over the 16-month
follow-up period (P¼ 0.011) (Table III). Mean differences between
the treatment groups at the follow-ups disclosed signiﬁcant
differences in favor of the PEþ SE group at 10 and 16 months for
WOMAC physical function score (Table IV). The standardized effect
sizes (95% conﬁdence interval) forWOMAC physical function scores
were 0.29 (0.67 to 0.09), 0.48 (0.91 to 0.06), and 0.47
(0.93 to 0.02) during the 4-, 10- and 16-month follow-ups,
respectively. The standardized effect sizes (95% conﬁdence interval)
using the last observation forward principle were 0.47 (0.85 to
0.08) and 0.44 (0.82 to 0.06) for 10 and 16 months, respec-
tively. No signiﬁcant differences between the groups were found
for WOMAC stiffness scores, SF-36 subscales, or PASE over the 16-
month follow-up period (Table III).
Discussion
No signiﬁcant difference between the PE and the PEþ SE group
was found for the main outcome, the WOMAC pain score, over the
16-month follow-up period. The effect sizes of 0.29 to 0.35 for
the WOMAC pain score in this study were not signiﬁcant and were
lower than previously reported. Hernandez-Molina et al., reported
a signiﬁcant effect size of 0.47 in patients with hip OA attending
exercise programs7. The mean values for the WOMAC pain score in
the PE and the PEþ SE groups indicated a small reduction of pain
from baseline to 10 and 16 months in both groups (Table III).
However, no signiﬁcant differences could be detected between
groups over time. The lower mean scores of pain seen at 10 and 16
months might be a consequence of people requiring THR surgery
dropped out from the study. Presumably, the 11 patients in the PE
group and the six patients in the PEþ SE group dropping out due to
THR surgery experienced more hip pain and limitations in physical
function at the time for surgery than at inclusion of the present
study. The mean WOMAC pain score for the drop-outs (at the last
observation for the 31 patients) revealed a higher mean value than
for patients still in the study. Accordingly, patients with severe
symptoms requiring surgery between the 4- and 16-month follow-
ups were not included in the analysis. The mean values for the 10-
and 16-month follow-ups (Table III) represented patients with hip
OA that were not eligible for surgery within a 16-month period.
Thus, based on intention-to-treat, per-protocol, and effect size
analyses, no signiﬁcant differences in pain could be detected
between the two interventions for patients with hip OA not
requiring THR surgery. From a bio-psychosocial perspective, the
experience of pain in patients with OA has been suggested to be
a product of a complex interaction between internal traits and
external inﬂuences affecting perception, beliefs and behavior29. For
the management of OA, educational interventions containing
information for the enhancement of coping strategy and self-efﬁ-
cacy have been recommended29. The PE program, offered to both
treatment groups in our study, contained information with the
purpose of increasing the patients’ beliefs in their own ability to
control their situation, and thereby potentially improve their
coping strategy10. A follow-up study evaluating the same PE
program that we have used in our study found a signiﬁcant
difference in pain scores between the group receiving PE and the
control group10. Since our study did not contain a control group
that did not receive education, it cannot be ascertained if the PE
alone could reduce pain.
Whilst the improvement found for the WOMAC physical func-
tion score in the PEþ SE group was signiﬁcant, the clinical impor-
tance of this is uncertain. The minimal difference in WOMAC
sub-scores thought necessary to achieve clinical signiﬁcance for
rehabilitation studies has been suggested to be 0.67e0.75 points(scale 0e10) for absolute values and 11e26% for relative values30,31.
In our study, WOMAC physical function scores between group
mean difference at 10 and 16 months were 8.4 and 7.7 mm (scale
0e100) and changes from baseline to 10 and 16 months were 25%
and 28%, respectively (Table IV). A relationship has been found
between baseline WOMAC physical function scores and the
perception of improvement in patients with knee OA, where a low
score at baseline required a smaller improvement to be considered
an improvement by the patient than would a high score at base-
line32. When applying the differences reported by Tubach et al. to
our study, the mean differences of absolute values of 8.4 and
7.7 mm between the groups at the 10- and 16-month follow-ups
would be small but of clinical importance. A plausible explanation
of low baseline values (mild to moderate symptoms) in our study
could be the inclusion criteria of a HHS of 60e95 points, repre-
senting a patient group seeking primary health care33,34. Twenty
patients (18%) in our study scored 10 mm onWOMAC pain33, and
31 patients (28%) scored 10 mm on WOMAC physical function.
However, the signiﬁcant differences seen in WOMAC physical
function score (Table III) were supported by signiﬁcant and robust
effect sizes for WOMAC physical function score at 10 and 16
months, respectively. The mean effect sizes found at 10 and 16
months are considered to be moderate35. But, the wide ranges of
the 95% conﬁdence intervals for the effect sizes imply a large inter-
individual variance and the magnitude of improved physical func-
tion can range from small to large between individuals.
Strength and limitations
One strength of the present study was the design; the study was
randomized and the outcome assessor was blinded. Moreover, we
included patients solely with hip OA and used interventions
specially designed for hip OA patients10,11.The included patients had
hip OAwithmild tomoderate symptomswhich is a commonly seen
patient group in primary health care33,34, but this patient group in
particular lacks evidence for treatment modalities5. Although the
patients scored mild to moderate symptoms on the WOMAC, they
sought medical care for their symptoms and at baseline they
differed signiﬁcantly in SF-36 physical function and bodily pain to
a general Norwegian population (Table II). In addition, a total of 17
patients (16%) had THR surgery within the 16-month period. Thus,
indicating that the included patients were patients withmanifested
symptoms in need of efﬁcient treatment modalities. Some limita-
tions need to be addressed in our study. Firstly, OA has shown to be
a disease with ﬂuctuating pain36 and the small mean changes
observed in the study could be an effect of patients seeking care in
a ﬂare period and the results being a consequence of natural course
or regression to the mean. Secondly, the observed results could be
a consequence of patients changing their behavior when entering
study, i.e., the Hawthorne effect. Thirdly, a common problem in
long-term follow-up studies is increasing drop-out rates as time
passes, which was particularly seen at the 16-month follow-up in
our study (Fig. 1). The 16-month results must therefore be
L. Fernandes et al. / Osteoarthritis and Cartilage 18 (2010) 1237e12431242interpreted cautiously. We calculated the sample size based on 90%
power and a drop-out rate of 10%, but ended up with a higher drop-
out rate than expected (28%). Knee pain or diagnosed knee OA was
among the exclusion criteria for this study, which was the reason
for excluding 16 of the initial 220 screened patients. The results
must therefore be limited to patients with hip OA, but with no
concomitant knee pain or knee OA.
The majority of studies evaluating exercise as treatment for
patients with OA encounter difﬁculties in compliance with treat-
ment. Over the 12-week exercise intervention in our study, the
patients in the PEþ SE group performed a median of 20 sessions,
where 75% of the patients performed 16 sessions. Because of
a wide variety in exercise prescription in both knee and hip OA
studies, no recommendation on optimal dosage (intensity,
frequency, duration) exists for patients with hip or knee OA31,37.
However, the general recommendation on the prescription of
strength training is to perform 8e10 types of exercises twice
a week38,39. In our study, almost all patients in the PEþ SE group
performed a minimum of eight different exercises per session, and
performed a mean of 1.6 exercise sessions per week for 12 weeks.
The duration of the exercise period and the amount of exercises
performed per session would be sufﬁcient in terms of evaluating
the potential effects of exercising39,40. The average of 1.6 exercise
sessions performed per week, on the other hand, is less than rec-
ommended. One patient in the PEþ SE group discontinued exercise
because of pain, but no other adverse events occurred. The exercise
program and its progression model11, may therefore be considered
feasible for patients with hip OAwith mild to moderate symptoms.
Comparison with other studies
The latest Cochrane review comparing land-based exercise with
no exercise found ﬁve RCTs including patients with hip and knee
OA, all with fewer than 50 participants per treatment allocation37.
Fransen et al.37 concluded that the meta-analysis results should be
considered inconclusive because of small samples of the RCTs and
heterogeneity both in outcomemeasures and content and duration
of the interventions. The present study is the ﬁrst to include
patients with isolated hip OA and to follow-up more than 50
patients per treatment allocation for the evaluation of a land-based
exercise program. Compared to effect sizes of 0.40 for pain and
0.37 for physical function from a meta-analysis evaluating exer-
cise among patients with knee OA31, the effect sizes of 0.26 to
0.35 for pain and0.29 to0.48 for physical function in our study
would be considered less for pain and similar for physical function.
At baseline, the activity level measured with PASE did not show any
differences between the patients with hip OA in our study and
elderly Norwegians17, nor did the PASE scores show any signiﬁcant
differences over the follow-up period between the two treatment
groups (Tables II and III). Consequently, the observed signiﬁcant
results found for WOMAC physical function scores could not be
explained by the patients’ general activity level but they may
possibly be an effect of the performance of speciﬁc exercises that
stimulate muscles and joint motion needed for daily activities, such
as stair walking, rising from a chair and putting on socks6,41. The SE
program focused on strengthening of lower extremities with the
goal of performing the exercises at an intensity level of 70e80% of
maximum11. The patients performing this exercise program may
therefore have increased their lower extremity strength, which is
a possible explanation for their improvement in physical function.
The present study is the ﬁrst to evaluate a SE program in addi-
tion to PE vs PE alone in patients with isolated hip OA. For the
reduction of pain, the combination of PEþ SE showed no differ-
ences compared to attending PE only. However, adding SE to PE
may be useful in improving physical function.Author contributions
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